Article

HF-125, a first-in-class computer-modeled novel inhibitor of Tribbles 2, for therapy of enzalutamide resistant, neuroendocrine prostate cancer

2026-04-30

Abstract excerpt

Second generation antiandrogens, such as enzalutamide, are commonly prescribed to treat advanced prostate cancer. However, enzalutamide resistant prostate cancer (ERPC) invariably develops with more aggressive features. Management of ERPC is extremely difficult not only because available therapies cannot effectively eliminate ERPC cells but also due to enhanced growth and highly metastatic features in ERPC cells t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4d1d5f82-5a4f-53fd-88b2-889917b4b28e
DOI: 10.64898/2026.04.27.720588

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

HF-125, a first-in-class computer-modeled novel inhibitor of Tribbles 2, for therapy of enzalutamide resistant, neuroendocrine prostate cancerDOI 10.64898/2026.04.27.720588Read

Tribbles 2 confers enzalutamide resistance in prostate cancer by promoting lineage plasticitySemantic proximity Read

Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticitySemantic proximity Read

The Silver Lining in BET Protein Targeting for Advanced Prostate Cancer Pharmacotherapy: Recent UpdatesSemantic proximity Read

Bioinformatics and system biology approaches for identifying potential therapeutic targets for prostate cancerSemantic proximity Read

Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells <i>in vitro</i>Semantic proximity Read

Exploration and Identification of Potential Therapeutic Targets and Biomarkers for Docetaxel Resistant Prostate CancerSemantic proximity Read

Emerging Developments in ETS-Positive Prostate Cancer TherapySemantic proximity Read

Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agentsSemantic proximity Read

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivoSemantic proximity Read

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.Semantic proximity Read

BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinationsSemantic proximity Read

BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2Semantic proximity Read